Analysts Are Bullish on These Healthcare Stocks: EPZM, CLBS

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Epizyme (NASDAQ: EPZM) and Caladrius Biosciences (NASDAQ: CLBS) with bullish sentiments.

Epizyme (NASDAQ: EPZM)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Epizyme (NASDAQ: EPZM), with a price target of $25. The company’s shares opened today at $17.10, close to its 52-week high of $18.50.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.6% and a 49.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $23, representing a 34.5% upside.

In a report issued on May 8, Oppenheimer also reiterated a Buy rating on the stock with a $26 price target.
Caladrius Biosciences (NASDAQ: CLBS)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Caladrius Biosciences (NASDAQ: CLBS) today and set a price target of $7. The company’s shares opened today at $5.24.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -6.7% and a 36.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as RegeneRx Biopharmaceuticals Inc, Biospecifics Technologies Corp, and Stemline Therapeutics Inc.

Caladrius Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $7.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.